Hansa CEO prepares for launching the first product in 2020
Swedish biopharmaceutical company Hansa Biopharma has hired a new CFO few months after the company raised USD 50 million to finance the commercialization of the company's candidate against organ rejection in kidney transplantations.
In November last year, Swedish biopharmaceutical company Hansa Biopharma - former Hansa Medical - raised no less than USD 50 million in a directed share issue. Back then, CEO Søren Tulstrup said that the money was to "accelerate our commercial preparations for the potential launch of imlifidase", that is, the company's lead candidate to inhibit organ rejection after kidney transplantations.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
